Charles Schwab Investment Management Inc. Boosts Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Charles Schwab Investment Management Inc. raised its position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 6.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 197,127 shares of the company’s stock after acquiring an additional 11,143 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Entrada Therapeutics were worth $3,408,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of TRDA. China Universal Asset Management Co. Ltd. acquired a new position in shares of Entrada Therapeutics in the fourth quarter valued at approximately $137,000. SG Americas Securities LLC boosted its holdings in Entrada Therapeutics by 44.0% in the fourth quarter. SG Americas Securities LLC now owns 14,036 shares of the company’s stock valued at $243,000 after purchasing an additional 4,291 shares during the period. Barclays PLC boosted its stake in shares of Entrada Therapeutics by 210.6% in the 3rd quarter. Barclays PLC now owns 45,110 shares of the company’s stock valued at $720,000 after buying an additional 30,585 shares during the period. Geode Capital Management LLC lifted its stake in Entrada Therapeutics by 8.8% in the third quarter. Geode Capital Management LLC now owns 576,451 shares of the company’s stock worth $9,214,000 after acquiring an additional 46,512 shares during the last quarter. Finally, Public Employees Retirement System of Ohio grew its holdings in Entrada Therapeutics by 89.1% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 16,259 shares of the company’s stock worth $260,000 after acquiring an additional 7,659 shares in the last quarter. 86.39% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Roth Mkm began coverage on shares of Entrada Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $29.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Entrada Therapeutics in a report on Tuesday, February 25th. Finally, Roth Capital upgraded Entrada Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th.

Entrada Therapeutics Price Performance

NASDAQ TRDA opened at $9.96 on Friday. The firm’s fifty day moving average price is $12.05 and its 200 day moving average price is $15.45. Entrada Therapeutics, Inc. has a 12 month low of $9.75 and a 12 month high of $21.79. The company has a market capitalization of $374.45 million, a price-to-earnings ratio of 6.26 and a beta of -0.14.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings data on Thursday, February 27th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.69. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. The company had revenue of $12.25 million for the quarter, compared to analyst estimates of $11.95 million. As a group, sell-side analysts forecast that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current year.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.